H-KMAELVHFL-OH

Ref. 3D-PP46660

Product Information

• Name: H-KMAELVHFL-OH
• Synonyms: NH2-Lys-Met-Ala-Glu-Leu-Val-His-Phe-Leu-OH

Description

Peptide H-KMAELVHFL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-KMAELVHFL-OH include the following: Facts and hopes in cancer antigens recognized by T cells W Brochier, O Bricard , PG Coulie - Clinical Cancer Research, 2023 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/29/2/309/713975 Prospective identification of cross-reactive human peptide-MHC ligands for T cell receptor based therapies RS Gejman , MG Klatt , A Chang , HF Jones, CY Oh - BioRxiv, 2018 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/267047.abstract Identification of the targets of T-cell receptor therapeutic agents and cells by use of a high-throughput genetic platform RS Gejman , HF Jones, MG Klatt , AY Chang - Cancer immunology , 2020 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/8/5/672/470110 Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy RA Morgan , N Chinnasamy, D Abate-Daga - Journal of , 2013 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2013/02000/Cancer_Regression_and_Neurological_Toxicity.7.aspx Neoantigen-targeted TCR-T cell therapy for solid tumors: how far from clinical application R Xu, S Du, J Zhu, F Meng, B Liu - Cancer Letters, 2022 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S030438352200324X T-Cell Receptor-Transduced T Cells: Clinical Experience PF Robbins - The Cancer Journal, 2015 - journals.lww.comhttps://journals.lww.com/journalppo/FullText/2015/11000/T_Cell_Receptor_Transduced_T_Cells__Clinical.7.aspx T-cell immunotherapies and the role of nonclinical assessment: the balance between efficacy and pathology ME Sharpe - Toxicologic Pathology, 2018 - journals.sagepub.comhttps://journals.sagepub.com/doi/abs/10.1177/0192623317752101 A library of cancer testis specific T cell receptors for T cell receptor gene therapy MAJ de Rooij, DFG Remst, DM van der Steen - Molecular Therapy , 2023 - cell.comhttps://www.cell.com/molecular-therapy-family/oncology/fulltext/S2372-7705(22)00142-5 de, Remst, DFG, Steen, DM an der, Wouters M Rooi - K., Hagedoorn, RS, Kester, MGD , 2023 - scholarlypublications https://scholarlypublications.universiteitleiden.nl/access/item%3A3616927/download Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials JG Pol , SA Acuna , B Yadollahi, N Tang - , 2019 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/2162402X.2018.1512329 Development and characterisation of anti-MCAM chimeric antigen receptor T cells H Mole - 2023 - core.ac.ukhttps://core.ac.uk/download/pdf/571217824.pdf MAGE-A antigens as targets for cancer immunotherapy E Schooten, A Di Maggio, PMPB en Henegouwen - Cancer treatment , 2018 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0305737218300537 The good and the bad of T cell cross-reactivity: challenges and opportunities for novel therapeutics in autoimmunity and cancer C Gouttefangeas , R Klein, A Maia - Frontiers in Immunology, 2023 - frontiersin.orghttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1212546 In-silico discovery of cancer-specific peptide-HLA complexes for targeted therapy A Dhanik, J R. Kirshner, D MacDonald, G Thurston - BMC , 2016 - Springerhttps://link.springer.com/article/10.1186/s12859-016-1150-2 The Melanoma-Associated Antigen Family A (MAGE-A): A promising target for cancer immunotherapy? A Alsalloum, JA Shevchenko, S Sennikov - Cancers, 2023 - mdpi.comhttps://www.mdpi.com/2072-6694/15/6/1779

• Brand: Biosynth